Selectin

Asia Pacific Glycomic Therapeutics Market Report 2023: Featuring Biomarin Pharmaceutical, Genzyme, Bayer, Glaxosmithkline & F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Glycosaminoglycan, Cataract, Bayer, Erythropoietin, GlaxoSmithKline, COVID-19, Enzyme replacement therapy, Government, Heparin, Precision medicine, Neuraminidase, Genzyme, Glycomics, Interferon, Glycoprotein, Alzheimer's disease, Proteoglycan, Gaucher's disease, Therapy, Center for Urban and Regional Analysis, Tissue plasminogen activator, Anemia, Research, Cancer, Thrombosis, Glycosphingolipid, GPI, ERT, Pharmaceutical industry, Fine chemical, Sanofi, Selectin

The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific.

Key Points: 
  • The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific.
  • The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
  • Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.
  • ; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics market in Asia Pacific.

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Retrieved on: 
Tuesday, August 2, 2022
Patient, Death, Neutrophilia, Phenotype, GLOBE, Water, LAD, Protein, Forward-looking statement, SEC, FTD, Birth, Biomarker, Probability, Private Securities Litigation Reform Act, SLX, Psychomotor retardation, Leukocytosis, ODD, Glycosylation, Lists of diseases, Therapy, COVID-19, Safety, Efficacy, Multi-system (rail), Quality of life, Drug development, Disease, Company, Nasdaq, Red blood cell, PRV, Program, Glycoprotein, Priority review, API, Hypotonia, CDG, Selectin, Pharmaceutical industry, Crossover, MD

AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-CDG).

Key Points: 
  • AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-CDG).
  • We are excited to announce the first patient was dosed in the LADDER pivotal trial.
  • This substantially advances the program toward an approved treatment option for patients and also a potential PRV, said Garry A. Neil, MD, President and Chief Executive Officer, Avalo Therapeutics.
  • The primary endpoint is the comparison of leukocyte function as determined by sialyl Lewis-X (SLx) antigen expression on leukocytes between treatment periods.

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Clinical trial, Therapy, Safety, Food, Preclinical development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, L'Ère du Verseau, Patient, PD-1, IND, Tumor microenvironment, Cancer, Macrophage, VSIG4, Selectin, FDA, Inflammation, VISTA, Soft tissue injury, Probability, Pharmaceutical industry, Vaccine

Verseau Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the companys investigational new drug (IND) application for its lead investigational product candidate, VTX-0811, a monoclonal antibody that binds to P-selectin glycoprotein ligand-1 (PSGL-1).

Key Points: 
  • Verseau Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the companys investigational new drug (IND) application for its lead investigational product candidate, VTX-0811, a monoclonal antibody that binds to P-selectin glycoprotein ligand-1 (PSGL-1).
  • The FDA has completed its 30-day safety review and granted approval for the company to proceed with the proposed first-in-human clinical trial of VTX-0811.
  • Verseau Therapeutics is advancing a new class of cancer immunotherapies to stimulate the conversion of immuno-suppressive, pro-tumorigenic macrophages into pro-inflammatory macrophages.
  • Verseaus first-in-class monoclonal antibody candidates, VTX-0811 targeting PSGL-1 and VTX-1218 targeting VSIG4, are progressing toward clinical trials.

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II

Retrieved on: 
Tuesday, December 1, 2020
Proteins, Medical specialties, Health, Hematology, Rare diseases, Leukocyte adhesion deficiency, Food and Drug Administration, Selectin, Investigational New Drug, LAD

and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study the use of CERC-803 to treat Leukocyte Adhesion Deficiency Type II (LAD II).

Key Points: 
  • and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study the use of CERC-803 to treat Leukocyte Adhesion Deficiency Type II (LAD II).
  • There are currently no FDA-approved therapies for patients suffering from LAD-II said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor.
  • LAD-II is caused by genetic mutations that result in deficiency in expression of surface adhesion molecule selectin, leading to defective leukocyte functions.
  • Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases.